Trials / Terminated
TerminatedNCT00088647
Study Evaluating MST-997 in Advanced Malignant Solid Tumors
A Phase 1 Dose-Escalation Study of Intravenous MST-997 Formulated in Intralipid 20% Administered Weekly in Subjects With Advanced Malignant Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this clinical research study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of intravenous (IV) MST-997 formulated in Intralipid 20% administered on a weekly schedule to subjects with advanced malignant solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MST-997 |
Timeline
- First posted
- 2004-08-02
- Last updated
- 2006-12-08
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00088647. Inclusion in this directory is not an endorsement.